Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".

Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM.

Circulation. 2019 Nov 12;140(20):e772-e773. doi: 10.1161/CIRCULATIONAHA.119.043149. Epub 2019 Nov 11. No abstract available.

PMID:
31710526
2.

Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis.

Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, Blaha MJ, McEvoy JW, Muntner P, Vaduganathan M, Correa A, Butler J, Shimbo D, Nambi V, deFilippi C, Seliger SL, Ballantyne CM, Selvin E, de Lemos JA, Joshi PH.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.043337. [Epub ahead of print] No abstract available.

PMID:
31707797
3.

"Zero": The New Superhero or Superhero in Training?

Nambi V, Virani SS, Jones PH, Ballantyne CM.

J Am Coll Cardiol. 2019 Nov 5;74(18):2331. doi: 10.1016/j.jacc.2019.08.1033. No abstract available.

PMID:
31672196
4.

Taking the Air Out of Oxygen Supplementation in Individuals With Diabetes and Acute Coronary Syndromes.

Aguilar D, Nambi V.

Diabetes Care. 2019 Nov;42(11):2019-2021. doi: 10.2337/dci19-0035. No abstract available.

PMID:
31636148
5.

Central arterial stiffness and retinal vessel calibers: the Atherosclerosis Risk in Communities Study-Neurocognitive Study.

Meyer ML, Klein BE, Klein R, Palta P, Sharrett AR, Heiss G, Nambi V, Wong TY, Tanaka H.

J Hypertens. 2019 Oct 3. doi: 10.1097/HJH.0000000000002252. [Epub ahead of print]

PMID:
31584520
6.

Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?

Howard CE, Nambi V, Jneid H, Khalid U.

J Am Heart Assoc. 2019 Oct 15;8(20):e012639. doi: 10.1161/JAHA.119.012639. Epub 2019 Oct 2. No abstract available.

7.

High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change.

Pokharel Y, Mouhanna F, Schneider ALC, Rawlings AM, Knopman DS, Nambi V, Virani SS, Hoogeveen RC, Alonso A, Heiss G, Coresh J, Mosley T, Gottesman R, Selvin E, Ballantyne C, Power MC.

J Am Geriatr Soc. 2019 Nov;67(11):2353-2361. doi: 10.1111/jgs.16092. Epub 2019 Jul 30.

PMID:
31359423
8.

Seven Metrics That Will Determine Your Cardiovascular Success or Failure.

Ballantyne CM, Nambi V.

JACC Heart Fail. 2019 Aug;7(8):648-650. doi: 10.1016/j.jchf.2019.04.008. Epub 2019 Jul 10. No abstract available.

PMID:
31302041
9.

Trends in Blood Pressure and High-Sensitivity Cardiac Troponin-T With Cardiovascular Disease: The Cardiovascular Health Study.

Tehrani DM, Fan W, Nambi V, Gardin J, Hirsch CH, Amsterdam E, deFilippi CR, Polonsky T, Wong ND.

Am J Hypertens. 2019 Sep 24;32(10):1013-1020. doi: 10.1093/ajh/hpz102.

PMID:
31232455
10.

Understanding by General Providers of the Echocardiogram Report.

Trang A, Kampangkaew J, Fernandes R, Tiwana J, Misra A, Hamzeh I, Blaustein A, Aguilar D, Shah T, Ballantyne C, Quinones M, Nagueh SF, Dokanish H, Virani SS, Deswal A, Kirkpatrick JN, Nambi V.

Am J Cardiol. 2019 Jul 15;124(2):296-302. doi: 10.1016/j.amjcard.2019.04.022. Epub 2019 Apr 24.

PMID:
31104774
11.

Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.

Jia X, Al Rifai M, Ramsey DJ, Ahmed ST, Akeroyd JM, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS.

Am J Med. 2019 Sep;132(9):e693-e700. doi: 10.1016/j.amjmed.2019.04.002. Epub 2019 May 17.

PMID:
31103643
12.

Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.

Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, Geisel MH, Lehmann N, Erbel R, Jöckel KH, van der Graaf Y, Verschuren WMM, Boer JMA, Nambi V, Visseren FLJ, Dorresteijn JAN.

Eur Heart J. 2019 May 18. pii: ehz239. doi: 10.1093/eurheartj/ehz239. [Epub ahead of print]

PMID:
31102402
13.

Metabolomic Pattern Predicts Incident Coronary Heart Disease.

Wang Z, Zhu C, Nambi V, Morrison AC, Folsom AR, Ballantyne CM, Boerwinkle E, Yu B.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1475-1482. doi: 10.1161/ATVBAHA.118.312236. Epub 2019 May 16.

PMID:
31092011
14.

ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Pokharel Y, Mouhanna F, Nambi V, Virani SS, Hoogeveen R, Alonso A, Heiss G, Coresh J, Mosley T, Gottesman RF, Ballantyne CM, Power MC.

Neurology. 2019 May 28;92(22):e2580-e2593. doi: 10.1212/WNL.0000000000007574. Epub 2019 May 1.

PMID:
31043469
15.

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM.

Circulation. 2019 Jun 4;139(23):2642-2653. doi: 10.1161/CIRCULATIONAHA.118.038772. Epub 2019 Apr 29.

PMID:
31030544
16.

Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.

Jia X, Akeroyd JM, Nasir K, Nambi V, Ballantyne CM, Petersen LA, Virani SS.

Circulation. 2019 Mar 5;139(10):1341-1343. doi: 10.1161/CIRCULATIONAHA.118.038691. No abstract available.

PMID:
30865483
17.

Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Saeed A, Sun W, Agarwala A, Virani SS, Nambi V, Coresh J, Selvin E, Boerwinkle E, Jones PH, Ballantyne CM, Hoogeveen RC.

Atherosclerosis. 2019 Mar;282:52-56. doi: 10.1016/j.atherosclerosis.2018.12.022. Epub 2018 Dec 30.

PMID:
30685442
18.

Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting.

Chauhan G, Adams HHH, Satizabal CL, Bis JC, Teumer A, Sargurupremraj M, Hofer E, Trompet S, Hilal S, Smith AV, Jian X, Malik R, Traylor M, Pulit SL, Amouyel P, Mazoyer B, Zhu YC, Kaffashian S, Schilling S, Beecham GW, Montine TJ, Schellenberg GD, Kjartansson O, Guðnason V, Knopman DS, Griswold ME, Windham BG, Gottesman RF, Mosley TH, Schmidt R, Saba Y, Schmidt H, Takeuchi F, Yamaguchi S, Nabika T, Kato N, Rajan KB, Aggarwal NT, De Jager PL, Evans DA, Psaty BM, Rotter JI, Rice K, Lopez OL, Liao J, Chen C, Cheng CY, Wong TY, Ikram MK, van der Lee SJ, Amin N, Chouraki V, DeStefano AL, Aparicio HJ, Romero JR, Maillard P, DeCarli C, Wardlaw JM, Hernández MDCV, Luciano M, Liewald D, Deary IJ, Starr JM, Bastin ME, Muñoz Maniega S, Slagboom PE, Beekman M, Deelen J, Uh HW, Lemmens R, Brodaty H, Wright MJ, Ames D, Boncoraglio GB, Hopewell JC, Beecham AH, Blanton SH, Wright CB, Sacco RL, Wen W, Thalamuthu A, Armstrong NJ, Chong E, Schofield PR, Kwok JB, van der Grond J, Stott DJ, Ford I, Jukema JW, Vernooij MW, Hofman A, Uitterlinden AG, van der Lugt A, Wittfeld K, Grabe HJ, Hosten N, von Sarnowski B, Völker U, Levi C, Jimenez-Conde J, Sharma P, Sudlow CLM, Rosand J, Woo D, Cole JW, Meschia JF, Slowik A, Thijs V, Lindgren A, Melander O, Grewal RP, Rundek T, Rexrode K, Rothwell PM, Arnett DK, Jern C, Johnson JA, Benavente OR, Wasssertheil-Smoller S, Lee JM, Wong Q, Mitchell BD, Rich SS, McArdle PF, Geerlings MI, van der Graaf Y, de Bakker PIW, Asselbergs FW, Srikanth V, Thomson R, McWhirter R, Moran C, Callisaya M, Phan T, Rutten-Jacobs LCA, Bevan S, Tzourio C, Mather KA, Sachdev PS, van Duijn CM, Worrall BB, Dichgans M, Kittner SJ, Markus HS, Ikram MA, Fornage M, Launer LJ, Seshadri S, Longstreth WT Jr, Debette S; Stroke Genetics Network (SiGN), the International Stroke Genetics Consortium (ISGC), METASTROKE, Alzheimer's Disease Genetics Consortium (ADGC), and the Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.

Neurology. 2019 Jan 16. pii: 10.1212/WNL.0000000000006851. doi: 10.1212/WNL.0000000000006851. [Epub ahead of print]

19.

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.

Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K, Smith SC Jr, Stone NJ, Petersen LA, Ballantyne CM.

Circulation. 2019 Jan 15;139(3):410-412. doi: 10.1161/CIRCULATIONAHA.118.034993. No abstract available.

PMID:
30586689
20.

Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?

Nambi V, Rohatgi A, Bhatt DL.

J Am Coll Cardiol. 2018 Dec 25;72(25):3270-3273. doi: 10.1016/j.jacc.2018.10.034. No abstract available.

PMID:
30573029

Supplemental Content

Loading ...
Support Center